Clinical review: Anti-TNFalpha therapies in uveitis: perspective on 5 years of clinical experience

SM Sharma, AR Nestel, RWJ Lee, AD Dick

Research output: Contribution to journalArticle (Academic Journal)

52 Citations (Scopus)

Abstract

Despite a lack of robust evidence, anti-TNF therapies are in wide use for the treatment of noninfectious ocular inflammatory diseases. There is a clear rationale, based on mechanistic and preclinical efficacy data, for their use in posterior segment intraocular inflammation. However, their increasing use for other indications has been largely extrapolated from the benefit observed in autoinflammatory and autoimmune systemic diseases. Given their cost and the potential for significant adverse events, this review highlights the evidence for their continued use, possibilities for switching anti-TNF agents, and ways of reducing the risk of therapy.
Translated title of the contributionClinical review: Anti-TNFalpha therapies in uveitis: perspective on 5 years of clinical experience
Original languageEnglish
Pages (from-to)403 - 414
Number of pages12
JournalOcular Immunology and Inflammation
Volume17(16)
DOIs
Publication statusPublished - 2009

Fingerprint Dive into the research topics of 'Clinical review: Anti-TNFalpha therapies in uveitis: perspective on 5 years of clinical experience'. Together they form a unique fingerprint.

  • Cite this